| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Center for the Study for Reproductive Biology and Women’s Health, Departments of Developmental and Molecular Biology and OB/GYN and Women’s Health,, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA
(Requests for offprints should be addressed to J W Pollard; Email: pollard@aecom.yu.edu)
* (H Zhang and T McElrath contributed equally to this work) Tamoxifen, a selective estrogen modulator (SERM) that has found clinical utility in the treatment of breast cancer, is an antagonist in the breast and an agonist in the uterus. These agonist actions in the uterus lead to an increased risk of endometrial cancer. In this study in mice we have analyzed the mechanism of action of tamoxifen in inducing cell proliferation in the uterine luminal epithelia. Tamoxifen induces a wave of DNA synthesis in these epithelial cells with kinetics similar to those seen after 17ß-estradiol (E2) treatment. However, by these criteria of mitogenicity, it is much less potent and never achieves full estrogenicity. This uterine epithelial cell proliferation is preceded by the mobilization of cyclin D1 from the cytoplasm to the nucleus which, together with CDK4, phosphorylates members of the Rb-retinoblastoma family of proteins, pRb and p107. Subsequent to this initial nuclear accumulation of cyclin D1, cyclin E and then cyclin A are induced that, together with the activation of CDK2, results in enhanced cyclin E- and cyclin A-dependent CDK2 kinase activity and further phosphorylation of pRb and p107. These actions of tamoxifen parallel those of E2. Tamoxifen also induced the classical estrogen water imbibition response. However, in this it was more potent, producing a maximal response at doses that do not affect DNA synthesis. This suggests that the uterotropic response is not an accurate predictor of the compound’s hyperplasia responses. We can conclude that, in its effects on proliferation, tamoxifen acts as a classical impeded estrogen and this suggests that the AF-1 transcription activation domain of the estrogen receptor that is activated upon both E2 and tamoxifen binding to this receptor regulates these responses in the uterus.
This article has been cited by other articles:
|
|
 |
|
  A. L. Niklaus, M. Aubuchon, G. Zapantis, P. Li, H. Qian, B. Isaac, M. Y. Kim, G. Adel, J. W. Pollard, and N. F. Santoro Assessment of the proliferative status of epithelial cell types in the endometrium of young and menopausal transition women Hum. Reprod., June 1, 2007; 22(6): 1778 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. O'Brien, T. J. Peterson, M. H. Tong, E.-J. Lee, L. E. Pfaff, S. C. Hewitt, K. S. Korach, J. Weiss, and J. L. Jameson Estrogen-induced Proliferation of Uterine Epithelial Cells Is Independent of Estrogen Receptor {alpha} Binding to Classical Estrogen Response Elements J. Biol. Chem., September 8, 2006; 281(36): 26683 - 26692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vivacqua, D. Bonofiglio, A. G. Recchia, A. M. Musti, D. Picard, S. Ando, and M. Maggiolini The G Protein-Coupled Receptor GPR30 Mediates the Proliferative Effects Induced by 17{beta}-Estradiol and Hydroxytamoxifen in Endometrial Cancer Cells Mol. Endocrinol., March 1, 2006; 20(3): 631 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chen, H. Pan, L. Zhu, Y. Deng, and J. W. Pollard Progesterone Inhibits the Estrogen-Induced Phosphoinositide 3-Kinase->AKT->GSK-3{beta}->Cyclin D1->pRB Pathway to Block Uterine Epithelial Cell Proliferation Mol. Endocrinol., August 1, 2005; 19(8): 1978 - 1990. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
